CN Patent

CN101541320B — 用于治疗痤疮皮损的阿达帕林和过氧化苯甲酰的组合

Assigned to Galderma Research and Development SNC · Expires 2014-04-09 · 12y expired

What this patent protects

本发明涉及阿达帕林或其药学上可接受的盐在制备用于减少痤疮皮损数量的药用组合物中的应用，所述应用通过联合或结合过氧化苯甲酰(BPO)，每日局部外用。推荐的治疗方法可以采用阿达帕林和BPO联合的药用组合物的形式，或者将两种药用组合物(一种含有阿达帕林而另一种含有BPO)伴随应用。

USPTO Abstract

本发明涉及阿达帕林或其药学上可接受的盐在制备用于减少痤疮皮损数量的药用组合物中的应用，所述应用通过联合或结合过氧化苯甲酰(BPO)，每日局部外用。推荐的治疗方法可以采用阿达帕林和BPO联合的药用组合物的形式，或者将两种药用组合物(一种含有阿达帕林而另一种含有BPO)伴随应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN101541320B
Jurisdiction
CN
Classification
—
Expires
2014-04-09
Drug substance claim
No
Drug product claim
No
Assignee
Galderma Research and Development SNC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.